Breaking News

Tweet TWEET

Dendreon to Present at 3rd Annual Cancer Immunotherapy Conference in New York

  Dendreon to Present at 3rd Annual Cancer Immunotherapy Conference in New
  York

2012 Cancer Immunotherapy: A Long-Awaited Reality Conference

Business Wire

SEATTLE -- October 03, 2012

October 3, 2012 – Dendreon Corporation (NASDAQ:DNDN) today announced the
company will be presenting at the MD Becker Partners’ 3rd Annual Cancer
Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m.
to 6:30 p.m. EDT on October 4, 2012, at the New York Academy of Medicine in
New York.

Mark W. Frohlich, MD, executive vice president of research and development and
chief medical officer at Dendreon, will provide an overview of PROVENGE^®
(sipuleucel-T), the first FDA-approved autologous cellular immunotherapy for
cancer. The presentation is expected to begin at 3:00 p.m. EDT.

A live and archived webcast of the company's presentation at the conference,
hosted by MD Becker Partners LLC, will be available at
www.regonline.com/mdb2012.

Dr. Frohlich will also participate in two panel sessions:

  *“Where Does Immunotherapy Fit into the Prostate Cancer Landscape?” - 9:00
    a.m. EDT
  *“Cancer Vaccines - Past, Present and Future” - 11:00 a.m. EDT

About the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference

"Cancer Immunotherapy: A Long Awaited Reality" is a unique, single-day
conference event that unites founding visionary researchers, clinicians,
business leaders, key investors, and other stakeholders to engage in
discussions, exchange information, highlight opportunities, and showcase
leading companies in the field of cancer immunotherapy.

AboutDendreon

Dendreon Corporationis a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company applies
its expertise in antigen identification, engineering and cell processing to
produce active cellular immunotherapy (ACI) product candidates designed to
stimulate an immune response in a variety of tumor types. Dendreon's first
product, PROVENGE^® (sipuleucel-T), was approved by the FDA inApril 2010.
Dendreonis exploring the application of additional ACI product candidates and
small molecules for the potential treatment of a variety of cancers. The
Company is headquartered inSeattle, Washington,and is traded on theNASDAQ
Global Marketunder the symbol DNDN. For more information about the Company
and its programs, visit http://www.dendreon.com.

Contact:

Dendreon Corporation
Corporate Communications
April Falcone, 206-829-1622
media@dendreon.com
 
Press spacebar to pause and continue. Press esc to stop.